Scarica l'app Stockscreener
3.22
1.26%
0.04
Dopo l'orario di chiusura:
3.25
0.03
+0.93%
Precedente Chiudi:
$3.18
Aprire:
$3.21
Volume 24 ore:
18,653
Relative Volume:
0.22
Capitalizzazione di mercato:
$92.09M
Reddito:
$709.00K
Utile/perdita netta:
$-43.14M
Rapporto P/E:
-0.7093
EPS:
-4.54
Flusso di cassa netto:
$-20.35M
1 W Prestazione:
-2.42%
1M Prestazione:
+25.29%
6M Prestazione:
+11.81%
1 anno Prestazione:
+8.05%
Intervallo 1D:
$3.16
$3.2859
Intervallo di 1 settimana:
$2.96
$3.6891
Portata 52W:
$1.922
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
Nome
OncoCyte Corporation
Settore
Industria
Telefono
510-775-0515
Indirizzo
1010 Atlantic Avenue, Suite 102, Alameda, CA
Confronta OCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
3.22 | 92.09M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
OncoCyte Corporation Borsa (OCX) Ultime notizie
OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World
OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World
OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks
OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo Finance
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, steady $4.25 target By Investing.com - Investing.com South Africa
Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com
OncoCyte: Q4 Earnings Snapshot - CT Insider
Oncocyte Corp Reports 2024 Success and 2025 Growth Plans - TipRanks
Oncocyte reports progress in organ transplant diagnostics By Investing.com - Investing.com South Africa
Oncocyte targets $20M in recurring revenue from 20 transplant centers by 2025 - MSN
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com
OncoCyte Corporation (OCX) Q4 Sales Increase - Nasdaq
Oncocyte reports progress in organ transplant diagnostics - Investing.com India
OncoCyte Corp Q4 2024 Earnings: Revenue Surges to $1.5 Million, Beating Estimates; EPS at -0.43 - GuruFocus.com
OncoCyte: Q4 Earnings Snapshot -March 24, 2025 at 04:29 pm EDT - Marketscreener.com
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts - GlobeNewswire
Oncocyte secures $29.1 million to advance FDA assay - MSN
OncoCyte Corp expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Oncocyte corp investor Patrick Smith buys $1,839 in shares - MSN
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - The Manila Times
Oncocyte Sets Key Q4 Earnings Webinar: Live Management Discussion Coming March 24 - StockTitan
OncoCyte Corporation (OCX): Among Top Insider Purchases Last Month - MSN
OncoCyte Announces Executive Promotions and Compensation Changes - TipRanks
OncoCyte Corp. to Host Earnings Call - ACCESS Newswire
OncoCyte stock soars to 52-week high, hits $3.48 By Investing.com - Investing.com Canada
OncoCyte stock soars to 52-week high, hits $3.48 - Investing.com India
OncoCyte Corporation (OCX): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
Oncocyte Raises $29.1 Million to Develop, Commercialize Transplant Assays - Orange County Business Journal
OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Broadwood Partners acquires OncoCyte shares worth $9.24 million - MSN
OncoCyte stock hits 52-week low at $1.92 amid market challenges - MSN
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million - MSN
Oncocyte corp’s Patrick Smith acquires shares worth $2.2 million By Investing.com - Investing.com South Africa
Oncocyte corp CFO buys $200,000 in stock - MSN
Oncocyte corp CFO buys $200,000 in stock By Investing.com - Investing.com Canada
Oncocyte Corp CFO Acquires 97,561 Shares in Private Placement - TradingView
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million By Investing.com - Investing.com Canada
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - The Manila Times
Exclusive: Oncocyte (OCX) CEO & CFO to Meet Top Investors at BTIG's Elite Healthcare Conference - StockTitan
Oncocyte Corp enters into securities purchase agreements - Medical Buyer
Broadwood Partners acquires OncoCyte shares worth $9.24 million By Investing.com - Investing.com Nigeria
OncoCyte Corporation Azioni (OCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):